Tag: Mind Cure - Psilocybin Alpha

New: Psychedelics 2021: A Year in Review

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

Post published:December 16, 2021
Post category:Press Release

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

Post published:December 14, 2021
Post category:Press Release

MINDCURE Provides Update on Studies and Clinical Trials

MINDCURE Provides Update on Studies and Clinical Trials

Post published:November 4, 2021
Post category:Press Release

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

Post published:October 28, 2021
Post category:Press Release

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

Post published:October 26, 2021
Post category:Press Release

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

Post published:September 30, 2021
Post category:Press Release

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Post published:September 27, 2021
Post category:Press Release

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

Post published:September 23, 2021
Post category:Press Release

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

Post published:September 16, 2021
Post category:Press Release

MINDCURE Announces Financial Results for Fiscal 2021

MINDCURE Announces Financial Results for Fiscal 2021

Post published:August 31, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.